Literature DB >> 9530504

Mutant genes in familial Alzheimer's disease and transgenic models.

D L Price1, S S Sisodia.   

Abstract

The most common cause of dementia occurring in mid- to late-life is Alzheimer's disease (AD). Some cases of AD, particularly those of early onset, are familial and inherited as autosomal dominant disorders linked to the presence of mutant genes that encode the amyloid precursor protein (APP) or the presenilins (PS1 or PS2). These mutant gene products cause dysfunction/death of vulnerable populations of nerve cells important in memory, higher cognitive processes, and behavior. AD affects 7-10% of individuals > 65 years of age and perhaps 40% of individuals > 80 years of age. For the late-onset cases, the principal risk factors are age and apolipoprotein (apoE) allele type, with apoE4 allele being a susceptibility factor. In this review, we briefly discuss the clinical syndrome of AD and the neurobiology/neuropathology of the disease and then focus attention on mutant genes linked to autosomal dominant familial AD (FAD), the biology of the proteins encoded by these genes, and the recent exciting progress in investigations of genetically engineered animal models that express these mutant genes and develop some features of AD.

Entities:  

Mesh:

Year:  1998        PMID: 9530504     DOI: 10.1146/annurev.neuro.21.1.479

Source DB:  PubMed          Journal:  Annu Rev Neurosci        ISSN: 0147-006X            Impact factor:   12.449


  158 in total

Review 1.  Function and dysfunction of the presenilins.

Authors:  S S Sisodia; S H Kim; G Thinakaran
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

Review 2.  Modulation of amyloid beta protein precursor processing as a means of retarding progression of Alzheimer's disease.

Authors:  S L Wagner; B Munoz
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

3.  A yeast genetic assay for caspase cleavage of the amyloid-beta precursor protein.

Authors:  P L Gunyuzlu; W H White; G L Davis; G F Hollis; J H Toyn
Journal:  Mol Biotechnol       Date:  2000-05       Impact factor: 2.695

4.  Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis.

Authors:  Kunihiro Uryu; Helmut Laurer; Tracy McIntosh; Domenico Praticò; Daniel Martinez; Susan Leight; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

Review 5.  Protein aggregates and dementia: is there a common toxicity?

Authors:  S Lovestone; D M McLoughlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

6.  The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus.

Authors:  Y Gao; S W Pimplikar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

7.  BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein.

Authors:  M Farzan; C E Schnitzler; N Vasilieva; D Leung; H Choe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 8.  Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.

Authors:  Vivian Hook; Gregory Hook; Mark Kindy
Journal:  Biol Chem       Date:  2010-08       Impact factor: 3.915

Review 9.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

10.  Cerebellar degeneration-related autoantigen 1 (CDR1) gene expression in Alzheimer's disease.

Authors:  Paolo Bosco; Rosario Spada; Salvatore Caniglia; Maria Grazia Salluzzo; Michele Salemi
Journal:  Neurol Sci       Date:  2014-04-29       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.